Serum Osteocalcin Level is Negatively Associated with Vascular Reactivity Index by Digital Thermal Monitoring in Kidney Transplant Recipients

Background and Objectives: Osteocalcin is the most abundant noncollagenous protein in bone matrix, which is considered a marker of bone formation. Previous studies indicate that circulating osteocalcin can be expressed by osteoblasts and even by osteoblast-like cells in vessel walls, and it is often associated with arterial stiffness. Our study aims to examine the potential association between osteocalcin levels and endothelial function among kidney transplant (KT) recipients. Materials and Methods: Fasting blood samples were obtained from 68 KT recipients. To measure the endothelial function and vascular reactivity index (VRI), a digital thermal monitoring test (VENDYS) was used. A commercial enzyme-linked immunosorbent assay kit was also utilized to measure serum total osteocalcin levels. In this study, a VRI of less than 1.0 indicated poor vascular reactivity; a VRI of 1.0–2.0 indicated intermediate vascular reactivity; and a VRI of 2.0 or higher indicated good vascular reactivity. Results: Our findings show that 8 KT recipients (11.8%) had poor vascular reactivity (VRI < 1.0), 26 (38.2%) had intermediate vascular reactivity (1.0 ≤ VRI < 2.0), and 34 (50%) had good vascular reactivity. Increased serum osteocalcin levels (p < 0.001) were found to be associated with poor vascular reactivity. Advanced age (r = −0.361, p = 0.002), serum alkaline phosphate level (r = −0.254, p = 0.037), and log-transformed osteocalcin levels (r = − 0.432, p < 0.001) were identified to be negatively correlated with VRI in KT recipients. Multivariable forward stepwise linear regression analysis revealed that the serum level of osteocalcin (β = −0.391, adjusted R2 change = 0.174; p < 0.001) and advanced age (β = −0.308, adjusted R2 change = 0.084; p = 0.005) were significantly and independently associated with VRI in KT recipients. Conclusions: Higher serum osteocalcin level was associated with lower VRI and poorer endothelial dysfunction among KT recipients.

Osteocalcin, a promising marker of osteoporosis: evaluation in post-menopausal females with osteoporosis

Background: Osteocalcin, has high affinity for calcium. In osteoporotic women, deficiency of calcium may lead to lowering of the formation of hydroxyapatite crystals. Thus, in the state of hypo mineralization, free osteocalcin available in the circulation. Therefore, present study was designed to evaluate significance of serum osteocalcin in diagnosis of osteoporosis, and relationship between Serum Osteocalcin and BMD (Bone mineral Density) in post-menopausal females with osteoporosis and without osteoporosis.Methods: One hundred and forty seven post-menopausal women between age 45 to 80 years attending the hospital OPD were studied. To be eligible for the study they had to have been postmenopausal for at least one year. The diagnosis of osteoporosis was made based on T-Scores (BMD) at the lumber spine (L1 to L4 and femaral neck) by DEXA (GE lunar Densitometer). Serum osteocalcin level was estimated by LIAISON osteocalcin assay. Patients with chronic conditions affecting skeletal health and patients on drugs affecting the skeleton were excluded from the study.Results: Serum osteocalcin level in post-menopausal female without osteoporosis was 9.87±1.04ng/ml, while post-menopausal female with osteoporosis had 22.62±2.25ng/ml suggesting significant increase in bone marker level in osteoporotic females (p<0.05.) Correlation study between BMD and osteocalcin showed strong Negative Correlation (r=-0.77, p<0.05).Conclusions: Serum osteocalcin can be considered as a specific marker of osteoblast function as its levels have been shown to correlate with bone formation rates. Thus, serum osteocalcin can be used for diagnosis and monitoring of response to therapy and this may be the better predictor than BMD.

ANALISIS KADAR OSTEOKALSIN SERUM OSTEOPENIA DAN OSTEOPOROSIS

Osteoporosis is a metabolic bone disease, characterized by decreased of bone mass density. Its incidence is higher in older population.Serum osteocalcin level is related to the rate of bone turnover. To analyze serum osteocalcin level on osteopenic and osteoporosis subjects.We examined 61 subjects for detecting osteopenia and osteoporosis by Sahara densitometer and measuring serum osteocalcin level byElecsys N-MID Osteocalsin Assay test. Of 21 men and 40 women, prevalence of osteopenia and osteoporosis were higher in women(57.5% and 32.5%) than men (42.9% and 23.8%). Most of osteoporosis subjects were in ≥ 60 years group and osteopenic subjects werein 50–59 years group (p<0.05). Mean of serum osteocalcin on osteoporosis subjects (26.70 ng/mL) was higher than osteopenic (23.78ng/mL) and normal (19.16 ng/mL) subjects (p<0.005). Prevalence of osteopenia and osteoporosis were higher in women than men. Theincidence of osteoporosis was related to the increase of age. Serum osteocalcin level was related to the severity of diagnosis category.

CORRELATION OF SERUM OSTEOCALCIN LEVEL AND PERIODONTAL ATTACHMENT LOSS WITH OSTEOPOROSIS RISK STATUS IN POSTMENOPAUSAL WOMEN

Objective: To assess the relationship between serum osteocalcin and periodontal clinical attachment loss (CAL) in postmenopausal women in relation to their osteoporosis risk status.Methods: A cross-sectional study was carried out on 71 postmenopausal women in Kenari District, Central Jakarta, Indonesia. The periodontal examination for all the subjects included a CAL measurement. The serum osteocalcin level was analyzed using ELISA.Results: The correlation between the serum osteocalcin level in patients with CAL and the risk of osteoporosis was analyzed with the Spearman test. The normal group had 29 subjects (40.84%), the osteopenic group had 23 subjects (32.39%), and the osteoporotic group had 19 subjects (26.76%). There was a significant correlation between CAL and the osteoporosis high-risk status (p<0.05) and no significant correlation between the serum osteocalcin level and the osteoporosis status (p>0.05).Conclusion: No correlation was found between CAL and the serum osteocalcin level (p>0.05).